Vincerx Pharma Company Description
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States.
Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability.
The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies.
It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor.
The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021.
Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Raquel Izumi |
Contact Details
Address: 1825 S. Grant Street San Mateo, Delaware 94402 United States | |
| Phone | 650 800 6676 |
| Website | vincerx.com |
Stock Details
| Ticker Symbol | VINC |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US92731L1061 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raquel E. Izumi Ph.D. | Co-Founder, Acting Chief Executive Officer, Secretary and Director |
| Dr. Ahmed M. Hamdy M.D. | Co-Founder and Chairman |
| Tom C. Thomas J.D. | Consultant |
| Alexander A. Seelenberger M.B.A. | Consultant |
| Dr. John C. Byrd M.D. | Founder and Chairman of Scientific Advisory Board |
| Kevin Haas | Acting Chief Financial Officer, Vice President of Finance and Corporate Controller |
| Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer |
| Gabriela Jairala | Vice President of Investor Relations and Corporate Communications and Chief of Staff |
| Karen Quarford M.B.A. | Vice President of Quality Operations and Compliance |
| Melissa Merrick SPHR | Senior Director of People and Culture and Head of Human Resource |